Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on August 7, 2023. The filing serves to announce the company's financial results for the three and six months ended June 30, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms that results for the three and six months ended June 30, 2023, were announced via a press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated August 7, 2023), as they are absent from this summary text.
- Confirm the company name is ReShape Lifesciences Inc., noting the discrepancy with the "Vyome Holdings, Inc." label in the request metadata.
- Review the full press release for any updated guidance or operational milestones for the second quarter of 2023.
- Check the company's liquidity status and cash runway, as these are critical for a biotech/life sciences firm but are not detailed in this 8-K cover page.